Clinical TrialsEnrollment has been completed for the Ph2b ACCESS and Ph2 ACCESS II trials for aleniglopron, with results expected by the end of 2025.
Financial StabilityThe company has a substantial cash balance of $883.5M, expected to fund operations through at least 2027.
Pipeline DevelopmentGPCR continues to offer significant pipeline optionality, indicating potential future growth opportunities.